Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | CPT2 | P23786 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL27591394 | 0.97 | ALDH1A1 (0.75) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8107350 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10934305 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1735796 | 0.97 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL9728576 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8604353 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL156916 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL597226 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL8758555 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7113923 | 0.95 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271635-A | Copper-iron bimetallic organic framework drug carrier, preparation method thereof and anticancer drug | 东莞市大朗医院 | 2024-07-02 | — | — | CN | disclosed |
| WO-2024128482-A1 | COMPOSITION FOR PRODUCING MATURE CARDIAC ORGANOID | 고려대학교 산학협력단 | 2024-06-20 | — | — | WO | disclosed |
| WO-2023063617-A1 | CARDIAC MESODERM CELL-BASED MATURE VENTRICULAR TYPE CARDIAC ORGANOID | 고려대학교 산학협력단 | 2023-04-20 | — | — | WO | disclosed |
| US-11324797-B2 | Plasmonics-active metal nanostar compositions and methods of use | DUKE UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220105099-A1 | METHOD FOR THE DETECTION OF DRUG-INDUCED ORGAN OR TISSUE INJURY IN IMPDH INHIBITOR TREATED PATIENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-07 | — | — | US | disclosed |
| CN-112300259-A | Autophagy protein beclin-1 and coding gene and application thereof | 中国科学院南海海洋研究所 | 2021-02-02 | — | — | CN | disclosed |
| US-20200276135-A1 | Dosage Forms and Related Therapies | PHILERA NEW ZEALAND LIMITED (NZ) | 2020-09-03 | — | — | US | disclosed |
| US-10543178-B2 | Dosage forms and related therapies | PHILERA NEW ZEALAND LIMITED (NZ) | 2020-01-28 | — | — | US | disclosed |
| US-10238610-B2 | Retinoid replacements and opsin agonists and methods for the use thereof | UNIVERSITY OF WASHINGTON (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190000778-A1 | Dosage Forms and Related Therapies | PHILERA NEW ZEALAND LIMITED (NZ) | 2019-01-03 | — | — | US | disclosed |
| WO-1996040178-A1 | USE OF CO-LOCALIZED ISLETS AND SERTOLI CELLS IN XENOGRAFT CELLULAR TRANSPLANTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5580884-A | ANTIMICROBIAL AGENTS | MONSANTO COMPANY (US) | 1996-12-03 | — | — | US | disclosed |
| EP-0698012-A1 | NOVEL DEOXYGALACTONOJIRIMYCIN DERIVATIVES | SEARLE & CO (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1995028167-A1 | METHODS OF TREATING DISEASE USING SERTOLI CELLS AND ALLOGRAFTS OR XENOGRAFTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| WO-1994026714-A1 | NOVEL DEOXYGALACTONOJIRIMYCIN DERIVATIVES | G.D. SEARLE & CO. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994017851-A1 | BILAYER COMPOSITE HYDROGELS FOR CORNEAL PROSTHESES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0502105-A4 | NON-REPLICATING RECOMBINANT-MADE RETROVIRAL PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS | — | 1993-02-24 | — | — | EP | disclosed |
| EP-0502105-A1 | NON-REPLICATING RECOMBINANT-MADE RETROVIRAL PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS | ONCOGEN LIMITED PARTNERSHIP (US) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007425-A1 | NON-REPLICATING RECOMBINANT-MADE RETROVIRAL PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS | ONCOGEN LIMITED PARTNERSHIP (US) | 1991-05-30 | — | — | WO | disclosed |
| US-4720459-A | Myelomas for producing human/human hybridomas | MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION, INC. (US) | 1988-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238610-B2 | Retinoid replacements and opsin agonists and methods for the use thereof | NR2E3, RARB, RARG | MEN1 4557/4885ALDH1A1 742/4885HMGCR 1377/4885 |
| US-10543178-B2 | Dosage forms and related therapies | SLC39A3, SLC39A11, SLC10A1 | MEN1 442/4885ALDH1A1 524/4885HMGCR 2520/4885 |
| US-20190000778-A1 | Dosage Forms and Related Therapies | SLC39A3, SLC39A11, SLC10A1 | MEN1 442/4885ALDH1A1 524/4885HMGCR 2520/4885 |
| US-20200276135-A1 | Dosage Forms and Related Therapies | SLC39A3, SLC39A11, SLC10A1 | MEN1 442/4885ALDH1A1 524/4885HMGCR 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.